# A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors

Source: https://onco.cc/trials/nct07083323/  
OnCo record `nct07083323` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HY05350 for injection in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.

## Summary

A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07083323 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 262 participants planned, started 2025-07-22 and due to reach its primary completion in 2028-03-31. Interventions recorded: HY05350 for injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07083323
- Phase: 1/2
- Setting: A Multicenter, Open-label Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Clinical Efficacy of HY05350 for Injection in Patients With MSLN-positive Advanced Solid Tumors
- Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd
- Enrolled: 262

## Sources

- ClinicalTrials.gov NCT07083323: https://clinicaltrials.gov/study/NCT07083323

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07083323.json